Zomedica Corp. operates as a development stage company. While it claims to be on the cusp of something big, chances are it’ll underwhelm in the coming months. Zomedica Pharmaceuticals Corp. [ZOM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -10.10. These include ZM-020 (a pathogen detection platform for dogs and cats) and ZM-017 (a platform to conduct cancer biopsies on dogs). The company has other candidates in its pipeline. So, what’s the play here, after its blockbuster run in the past three weeks? Pour autoriser Verizon Media et nos partenaires à traiter vos données personnelles, sélectionnez 'J'accepte' ou 'Gérer les paramètres' pour obtenir plus d’informations et pour gérer vos choix. But, until further developments come out, it’s tough to handicap whether the company will find success with either one. Investors should also keep an eye on sector updates as ZOM has historically followed its peers on positive news. At the very opening of the session, the stock price was $0.17 and reached a high price of $0.17, prior to closing the session it reached the value of $0.17. 1125 N. Charles St, Baltimore, MD 21201. Don’t Miss This Chance for Life-Changing Profits With Small High-Growth Stocks, Every Investor Should Own at Least Some of These Stocks, What Square’s $50 Million Bitcoin Investment Means for You, This Bill Gates-Backed Company Is Making Big Waves in the Battery World, 5G Stocks: This New Era of Massive Profits Just Began. Put it all together, and the recent moves in this penny stock are fishy to say the least. All rights reserved. Yes, there may be potential with its flagship pet diagnostic platform TRUFORMA. CLF, ZOM among premarket losers. As of 1:30 p.m. EST, Zomedica… Admittedly, there’s more to Zomedica’s pipeline than just TRUFORMA. 02/11: Zomedica Corp. Get the latest news and breaking stories for Zomedica Pharmaceuticals (ZOM) stock. More Details Shares of Zomedica (NYSEMKT:ZOM) soared on Monday, extending the veterinary health company's torrid gains in recent days. Post-Market 0.02 (0.75%) Zomedica Corp. Common Shares (ZOM) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Except for online chatter, these penny stocks in the healthcare sector had no apparent reason to spark a wild ride.Thanks to the Robinhood platform, … In short, buying this stock is more of a gamble than a sound investment. Zomedica's upsized offering comes after the stock skyrocketed 1,070.9% year to date through Monday, compared with the S&P 500's 4.3% gain over the same time. Zomedica (ZOM), Tonix Pharmaceuticals (TNXP), and Biolase (BIOL) all were on a roller-coaster ride over the past few days. Click here to see what Matt has up his sleeve now. Zomedica Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Avoid ZOM stock at all costs. High volatility in Zomedica Pharmaceuticals Corp stock price on Wednesday which ended trading at $2.55 (Updated on February 10, 2021) Buy or Hold candidate since 2020-11-13 Gain 2 592.71% PDF . On the date of publication, neither Matt McCall nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in the article. Nothing’s guaranteed when it comes to early-stage healthcare companies. One word: avoid! One company recording unseemly gains, is Zomedica Pharmaceuticals . Copyright © Vous pouvez modifier vos choix à tout moment dans vos paramètres de vie privée. Announces Closing of $173.5 Million Bought Deal: GL. 1125 N. Charles St, Baltimore, MD 21201. “Zomedica Pharmaceuticals Corp. (AMEX: ZOM) The 36 Months beta value for ZOM stocks is at 0.06, while of the analysts out of 0 who provided ratings for Zomedica Pharmaceuticals Corp. stocks as a “buy” while as overweight, rated it as hold and as sell. Sure, if the hype continues and the company releases more positive news, shares could move upward from today’s prices. Zomedica Pharmaceuticals Corp. (ZOM.V) (CVE ZOM) News Headlines Today Source: All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Instead of assessing the long-term potential of TRUFORMA, speculators have mostly bought this on hype alone. Those who got in early and bought back when ZOM stock was changing hands at 23 cents per share are sitting pretty. Put simply, shares more than reflect the prospects of TRUFORMA, and then some. quotes delayed at least 15 minutes, all others at least 20 minutes. MoneyLine Podcast: These Stocks Are the Future. The company’s stock price has collected -2.04% of loss in the last five trading sessions. But those who got in at $1 per share and above? And that’s the problem with ZOM stock. It creates products for companion animals by focusing on the unmet needs of clinical veterinarians. Article printed from InvestorPlace Media, https://investorplace.com/moneywire/2021/01/zom-stock-zomedica-pharmaceuticals-is-mostly-hype/. Press Release reported 1 hour ago that Thinking about buying stock in Zomedica, Mogo Inc, AXT Inc, IMAC Holdings, or Himax Technologies? I understand why some may be interested in diving into this “hot stock.” Although right now it’s operating with zero revenue, that could all change once TRUFORMA debuts. The jury’s still out. But news of this product’s commercial release was announced back in November. At first glance, one may think the rapid rise in Zomedica shares is due to game-changing developments with TRUFORMA. Chances are, it’s due to the recent large-scale hyping up of the stock online. Nasdaq Nos partenaires et nous-mêmes stockerons et/ou utiliserons des informations concernant votre appareil, par l’intermédiaire de cookies et de technologies similaires, afin d’afficher des annonces et des contenus personnalisés, de mesurer les audiences et les contenus, d’obtenir des informations sur les audiences et à des fins de développement de produit. Découvrez comment nous utilisons vos informations dans notre Politique relative à la vie privée et notre Politique relative aux cookies. Press Release reported on 10/02/20 that Zomedica Announces Name Change. Zomedica Pharmaceuticals Corp. has prepared a Management Proxy Circular and Proxy Statement dated August 6, 2020, as well as a supplement thereto dated August 20, … Investors excited about a new diagnostic platform have been pushing shares of Zomedica (NYSEMKT:ZOM) through the roof recently. Once investors realize this stock is mostly sizzle (with very little steak), shares will crater back to prior price levels. They could wind up “holding the bag,” so to speak. ZOMEDICA: Pharmaceuticals Closes Offering of 91.3 Million Shares With Gross Proceeds of $173.5 Million: MT. All told, Zomedica Pharmaceuticals Corp. ZOM has strung together solid data and demonstrated underlying fundamentals. So, if not the pending commercial debut of TRUFORMA, what was it that got investors excited for ZOM stock? ANN ARBOR, Mich., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM) (“Zomedica” or the “Company”) a veterinary diagnostic and pharmaceutical company, today announced that it has received approval of its application to delist its common shares from the TSX Venture Exchange (“TSXV”) effective at the close of business on … 02/11: ... All news about ZOMEDICA CORP. 02/11: ZOMEDICA: Pharmaceuticals Closes Offering of 91.3 Million Shares With Gross Pro.. MT. Granted, this helped to increase the company’s cash position by more than $40 million. But, given the recent pumping of this stock online and the subsequent shareholder dilution, the risk of heavy losses vastly outweigh the potential for shares to rally another 100% (or more) from here. Get today's Zomedica Pharmaceuticals Corp stock price and latest ZOM news as well as Zomedica Pharma real-time stock quotes, technical analysis, full financials and more. Zomedica Pharmaceuticals Corp. ZOM 2.66 0.11 (4.31%). The company’s stock price has collected 59.32% of gains in the last five trading sessions. Suspicions rise further when you consider that many investors exercised warrants they held to buy Zomedica shares at lower prices. But, no matter the cause, there’s no reason to chase this rally. Shares are already up by ~330% since the turn of the year, although the surge has nothing to do with high short interest. Zomedica Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Matthew McCall left Wall Street to actually help investors –by getting them into the world’s biggest, most revolutionary trends BEFORE anyone else. In … Which Ones Should You Invest In? With his next-generation approach to investing, Matt McCall finds better stocks for you to invest in — not the same old companies over-hyped on Wall Street. ET on InvestorPlace.com ZOM Stock: Why Zomedica Shares Are on the Move Again Today Don’t let its 342% rally since Jan. 4 cloud your judgment. Once the hype subsides, shares will again trade on their fundamentals. Zomedica Pharmaceuticals (ZOM) Announces $25 Million Bought Deal Offering of Common Shares Article Related Press Releases ( 1 ) Stock Quotes (1) FREE Breaking News Alerts from StreetInsider.com! However, given that these outstanding warrants had exercise prices of 20 cents per share or below, this capital raise came at the price of heavy dilution. Many may see Zomedica’s recent move higher and believe, even after its triple-digit rally, that you can still “get in on the ground floor” at the stock’s current price levels. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Pharmaceuticals (NYSEMKT:ZOM) stock is the latest pump-and-dump looking to take investors for a ride. Informations sur votre appareil et sur votre connexion Internet, y compris votre adresse IP, Navigation et recherche lors de l’utilisation des sites Web et applications Verizon Media. Find the latest Zomedica Corp. (ZOM) stock quote, history, news and other vital information to help you with your stock trading and investing. Zomedica Pharmaceuticals Corp News. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. Zomedica Pharmaceuticals Corp. ZOM also noted assets of $32.76 million at the end of the last quarter. Zomedica’s product portfolio will include innovative diagnostics and therapeutics that emphasize patient health and practice health. ANN ARBOR, Mich., May 26, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary diagnostic company, today announced the pricing of a public offering of 133,333,333 common shares (or common share equivalents) of the Company, together with warrants to purchase up to 133,333,333 common shares, … It’s Time to Order Profits Off the Table From DoorDash, Latest Bitcoin Breakout Highlights an Overlooked Opportunity. Zomedica Pharmaceuticals Corp. (AMEX:ZOM) went up by 27.68% from its latest closing price compared to the recent 1-year high of $0.50. And then some, when you factor in the heavy dilution from the recent exercising of options. Bottom line: Don’t get caught holding the bag. GME, AMC and DOGE: Stop Worrying and Love the Bubble >>> READ MORE, Matt McCall and the InvestorPlace Research Staff. That is to say, buying in at inflated prices only to see shares crater as it becomes apparent Zomedica is not the next big name in pet healthcare. But, as it stands now, this is a company with zero revenue and around $90 million in cash — but a $833.7 million market capitalization. While the company could surprise, and TRUFORMA could take off as the hottest thing in veterinary medicine, don’t hold your breath. The average price we get from analysts is $0.50 which is -$0.24 below current price. 2021 InvestorPlace Media, LLC. Zomedica Pharmaceuticals (NYSEMKT:ZOM) is on the move this morning after the under-the-radar play in the pet care space named a new CEO to lead the … Zomedica (ZOM) Stock Price and News: Critical Tuesday test for the pharma firm's shares ... Stocks of the Ann Arbor, Michigan-based pharmaceutical firm … Zomedica Corp. was founded in 2015 and … ZOM: Get the latest Zomedica stock price and detailed information including ZOM news, historical charts and realtime prices. Zomedica Pharmaceuticals (NYSEMKT: ZOM), an under-the-radar play on the pet care space, is having an impressive time in the stock market today. Zomedica Pharmaceuticals Corp. (ZOM) is priced at $0.15 after the most recent trading session. A recent allegedly paid-for video endorsement from Carol Baskin (of Tiger King fame) helps bolster this theory. Zomedica Pharmaceuticals (NYSEMKT: ZOM) stock is the latest pump-and-dump looking to take investors for a ride.Don’t let its 342% rally since Jan. 4 … Includes articles, videos and real-time news from StockTwits. It focuses on the discovery, development, and commercialization of drugs, novel drug delivery systems, devices, and diagnostics for the health and wellness of companion animals, such … Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Get the hottest stocks to trade every day before the market opens 100% free. Copyright © 2021 InvestorPlace Media, LLC. Success investing in this sector involves more than just rushing out and buying on the headlines alone. Zomedica Pharmaceuticals Corp. operates as a veterinary pharmaceutical company in the United States. Once this happens, expect them to fall fast toward prior price levels. The stock has already … Click here to see what Matt has up his sleeve now. Zomedica Pharmaceuticals Is Mostly Hype Jan. 21, 2021 at 12:55 p.m. Zomedica Pharmaceuticals Corp. (AMEX:ZOM) went down by -2.04% from its latest closing price compared to the recent 1-year high of $0.50. By Seeking Alpha - 11 hours ago. More likely than not, however, Zomedica is going to fall short. Zomedica Pharmaceuticals stock price prediction is an act of determining the future value of Zomedica Pharmaceuticals shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation.The successful prediction of Zomedica Pharmaceuticals stock future price could yield a significant profit. Latest news headlines for Zomedica Pharmaceuticals Corp with market analysis and analyst commentary. Yahoo fait partie de Verizon Media. As a result, the company’s valuation more than reflects the potential value of this flagship product. While it’s possible this soon-to-be commercialized diagnostic platform will revolutionize veterinary medicine, is it probable? All rights reserved.
Marion County, Illinois Population, Anointing Oil Prayer For Protection, How To Turn On Wifi On Msi Laptop Windows 10, Difference Between Combinational And Sequential Circuits Pdf, Aerosmith Album Cover Images, Nba En Vivo Online Gratis, Hitman 2 Isle Of Sgail, Dentures Make My Upper Lip Stick Out,
